The Study On Effect Of Aminoguanidine Eye-drops On Diabetic Cataracts In Rats

Cataract is the leading cause for blindness worldwide. In the world, about 17 million people are blind because of cataract formation. Operations are the only effective treatment for cataract at present. However, the complication of operations such as posterior capsule opacification, glaucoma, retina detachment, etc and the high costing of operations drive the study of pharmaceutical approaches to the maintenance of lens transparency.Because of dietary, depression and cigarette smoking, the number of diabetic is on the increase and the number of diabetic cataract is growing with aging of the population. It is vital in the diabetic cataract formation that the non-enzymic glycosylation of the lens structural proteins by glucosamine induces conformational changes in the lens. Aminoguanidine (AG) inhibits a variety of diabetic complications by trapping the reactive carbonyls and preventing the formation of advanced glycation endoproducts (AGEs). It had been reported that AG intraperitoneal injection could delay the progression of diabetic cataract. But the intraperitoneal injection is not suitable in clinic for the complication and the complexity. This study has explored the effect of AG eye-drops on the diabetic cataract.